OPDP says website for weight-loss drug misleads

The FDA's Office of Prescription Drug Promotion said in a note to Citius and Akrimax that their website for weight-loss drug Suprenza omits material information, such as risk factors for certain patients and the patient population for which the drug is indicated. The OPDP also said the use of the word "lean" in the ad misleads consumers into thinking they will become slim or slender if they take the drug, but leanness was not a primary endpoint in clinical trials.

View Full Article in:

Medical Marketing & Media · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC